Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
STAFFORD, Texas, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
This expansion is in addition to the previously announced Microsoft for Startups program.PredicTcell, Tevogen Bio’s proprietary technology, is designed for...
NEW YORK, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Data corroborate previously reported preclinical data demonstrating certepetide’s ability to enhance the effectiveness of immunotherapy Preliminary results to be presented...
Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM ESTMIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS),...
STAFFORD, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
Collaboration to take Cytovation’s synthetic peptide, CY-101, into a Phase 2 trial for patients with adrenocortical carcinomaCancer Research UK’s Centre...
NEW YORK, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
CHICAGO, IL / ACCESS Newswire / January 22, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a...
Phase II trial evaluating efti in combination with radiotherapy plus KEYTRUDA® (pembrolizumab) in patients with soft tissue sarcoma reaches enrolment...
Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population...
– Casdozokitug, in combination with atezolizumab/bevacizumab, final data demonstrate durability of response and improvement in depth of response including a...
STAFFORD, Texas, Jan. 22, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused...
First shared at a recent Japanese Society of Digital Pathology meeting, the company is forging a global alliance with a...
SON-1010, after receipt of data suggesting clinical benefit when administered as a monotherapy in patients with advanced solid tumors, enters...
GAITHERSBURG, Md., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma”), a discovery and development...
– Presented data includes a 97% Calculated Objective Response Rate (ORR) of study subjects following treatment with VP-315 – Posters...
Transformative Scientific Breakthrough Pioneered by Spencer Trask & Co. Venture Osiris Therapeutics NEW YORK, Jan. 16, 2025 /PRNewswire/ -- The...
BioVaxys Technology Corp. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation...
BioVaxys Technology Corp. invites individual and institutional investors as well as advisors and analysts to attend its real-time, interactive presentation...